Exit of cancer diagnostician GILUPI successfully completed
The Chinese company Hebei Viroad Biotechnology Co. Ltd. acquires all shares of the previous shareholders
Potsdam - January 2019, a gradual acquisition of all shares by the Chinese MedTech investor Hebei Viroad Biotechnology was agreed between the former shareholders of GILUPI GmbH, which is based in Potsdam. The investor has been strategically active at GILUPI GmbH since 2012. GILUPI now announces the successful sale of the remaining shares in January 2019.
Until now, the Chinese investor has supported and sought the approval and market launch of the GILUPI product CellCollector® in China. The innovative medical device CellCollector® enables the detection (isolation) of tumor cells in the blood of patients. Since June 2017, the CellCollector® has been approved for marketing in China and has been protected by patent law. Initial studies on its application in China have already been successfully completed and a large number of publications has also been published. Together with its partner Viroad, GILUPI is now working to further expand its acceptance in the Chinese market and to expand the product's applications.
About Gilupi GmbH
GILUPI GmbH was founded in 2006 and developed and commercialized in vivo diagnostics for early detection and prognosis in the indications of colorectal cancer, lung and prostate cancer. One focus is on the isolation of circulating tumor cells (CTCs). ILB participated through its BFB Beteiligungsfonds Brandenburg GmbH, Brandenburg Kapital GmbH and the venture capital funds of the savings banks of the State of Brandenburg which it manages.
For more information, see www.brandenburg-kapital.de and www.gilupi.de.
